Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWT020 in advanced cancer
NCT06092580Phase 1Recruiting
- Sponsor
- Anwita Biosciences
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AWT020 in solid tumor and malignant lymphoma, sponsored by Anwita Biosciences. Primary endpoint: Treatment-related adverse events. Started Sep 2023; status: recruiting.
02
Drugs
AWT020
03
Conditions
solid tumormalignant lymphoma
Beyond the preview
Go deeper on NCT06092580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092580.